The market size of China’s bio drugs is predicted to reach RMB 326.9 billion in 2021, with a YOY increasing rate of 17.99%, which signposts the golden age of the Chinese biopharmaceutical industry. bioLIVE China, together with its concurrent high-end conference Bio S&T, will focus on the most heated subjects on life science, life technology and innovative drugs, and facilitate a one-stop platform for biopharmaceutical manufacturers and technical service providers.
The exhibition is a feast of the practitioners in pharmaceutical industry, which gathers high-quality enterprises at home and abroad and attracts worldwide customer groups. As an exhibitor, we appreciate it much to the organizer for providing such a global platform for we exhibitors, so that we have the opportunity to show our business and products. It also creates many chances of international cooperation, promoting the internalization process of China’s pharmaceutical industry.
Biologics and New Therapies
Bioprocessing, Manufacturing and Solutions
Biotechnology and R&D services